Fig. 5

Reparixin inhibits NOD1/2-induced tumorigenesis of CSCC cells by inhibiting the secretion of IL-8. A IL-8 levels secreted by Siha/LV-NOD1 and Siha/LV-NOD2 cells with NOD1 and NOD2 knockdown (left panels), or ML-130 pretreatment (right panels). B IL-8 levels secreted by Siha/LV-NOD1 and Siha/LV-NOD2 treated with EVP4593 (NF-κB inhibitor). C Proliferation rates of Siha/LV-NOD1 and Siha/LV-NOD2 cells treated with Reparixin (R), EVP4593 (E), SCH772984 (S), and their combination. D, E Representative images of transwell assays showing migration and invasion of Siha/LV-NOD1 and Siha/LV-NOD2 cells treated with Reparixin or EVP4593. The percentages are shown on the right. ELISA and transwell assays were performed in triplicates and CCK8 assay in five replicates. F, G Immunoblot showing expression of ERK/p-ERK and NF-κB/p-NF-κB in the Siha/LV-NOD1 and Siha/LV-NOD2 CSCC cells (data are from three independent experiment) transfected with siRNAs. All data are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001